头孢唑林与利福平联用致凝血功能障碍
本文报告一例86岁男性在人工髋关节置换术后感染治疗中,接受利福平与头孢唑林联合方案后出现手术部位明显出血及凝血酶原时间、INR显著升高的不良事件。Naranjo量表判定头孢唑林与利福平为INR升高的很可能原因,利物浦避免性评估工具将该事件归类为「绝对可避免」。作者提示含利福平方案治疗保留假体的葡萄球菌性假体关节感染时,应通过适当监测预防低凝血酶原血症的不良后果。
要点
- 利福平联合头孢唑林可能导致低凝血酶原血症和INR升高,尽管被认为罕见。
- 使用含利福平的抗感染方案时应适当监测凝血指标,以预防出血不良后果。
- 该不良事件经评估为「绝对可避免」,提示监测与预防措施具有可操作性。
核心结论
- 利福平与头孢唑林联合所致低凝血酶原血症虽罕见,但其不良后果可通过适当监测加以预防。
研究设计与样本
- 本文为个案报告,描述一例86岁男性患者的不良事件经过,未报告样本量与对照设计。
主要发现
- 患者在术后第9天由头孢曲松改为头孢唑林,第二次清创并延长头孢唑林与利福平治疗后3天,因手术部位明显出血就诊,凝血酶原时间与INR显著升高。
- 未识别出其他潜在 contributing 因素;Naranjo不良反应概率量表判定头孢唑林与利福平为INR升高的很可能原因。
- 利物浦不良反应避免性评估工具将该不良事件归类为「绝对可避免」。
关键数值与推荐
- Naranjo不良反应概率量表判定头孢唑林与利福平为INR升高的很可能原因。
- 利物浦不良反应避免性评估工具将该事件归类为「绝对可避免」。
临床怎么用
- 对接受含利福平方案(尤其联合头孢唑林)的患者,应关注凝血功能监测,以便早期发现低凝血酶原血症并预防出血。
- 在甲氧西林敏感葡萄球菌感染中,头孢唑林常作为确定性抗菌方案的β-内酰胺骨干用药,联合利福平时需将凝血监测纳入管理。
局限性
- 本文为单个病例报告,无法确立因果关系或估计发生率。
- 原文未报告凝血指标的具体数值、监测频率或预防性干预措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify risk factors that may predispose patients to rifampin- and cefazolin-induced coagulopathy. SUMMARY: An 86-year-old man with a history of rheumatoid arthritis on chronic prednisone and stage 3 chronic kidney disease, notably not on warfarin, presented to the hospital with a 10-day history of right hip pain, swelling, and drainage after a recent right total-hip arthroplasty. The patient underwent a combination of surgical intervention and medication therapy with rifampin and ceftriaxone. After discharge and at postoperative day 9, ceftriaxone was changed to cefazolin due to increasing alkaline phosphatase levels. Four weeks after the initial debridement, antibiotics, and implant retention, the patient underwent a second irrigation and debridement due to persistent infection. Cefazolin and rifampin therapy was extended. Three days later, the patient presented to the emergency room with significant bleeding at the surgical site and a profoundly elevated prothrombin time and international normalized ratio (INR). No potential contributors were identified. The Naranjo adverse drug reaction probability scale identified cefazolin and rifampin as the probable cause of elevated INR. The Liverpool adverse drug reaction avoidability assessment tool classified this adverse event as "definitely avoidable." CONCLUSION: Rifampin-containing regimens are often recommended to treat staphylococcal prosthetic joint infections when the implant is retained. In methicillin-susceptible staphylococcal infections, cefazolin is routinely employed as the β-lactam backbone of definitive antimicrobial regimens. Although rifampin- and cefazolin-induced hypoprothrombinemia seems to be rare, adverse consequences of its occurrence may be prevented with appropriate monitoring.
引用
- Castillo Almeida NE, Stevens RW, Gurram P, et al. Cefazolin and rifampin: A coagulopathy-inducing combination. Am J Health Syst Pharm. 2021. PMID: 34000006. doi:10.1093/ajhp/zxab210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。